Powering Recovery, Renewing Hope
Indivior (indivior.com) earns a Brand Analyzer score of 82 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 3417 Healthcare brands analyzed, Indivior ranks in the 86th percentile (category average 72, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 98/100, Digital Presence 94/100, Visual Identity 98/100, Messaging Clarity 95/100, Trust Foundation 87/100, AI Discoverability 74/100, Brand Authority 44/100.
Indivior is a specialty pharmaceutical company headquartered in Richmond, Virginia, founded in 1994 and owned by Northern Cross. It focuses exclusively on opioid use disorder, developing evidence-based treatments aimed at supporting long-term recovery. The company positions itself as a leader in addiction medicine, combining scientific research with a mission to expand treatment access, reduce stigma, and help individuals manage opioid use disorder as a chronic but treatable condition. Its primary audience includes patients, healthcare providers, and the broader medical community involved in addiction care.
| Brand Name | Indivior |
|---|---|
| Domain | indivior.com |
| Industry | Healthcare |
| Founded | 1994 |
| Headquarters | Richmond |
| Parent Company / Owner | Northern Cross |
| Main Competitors | Alkermes, Braeburn Pharmaceuticals, Camurus, Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals (81/100) |
Moz Domain Authority 53/100 vs category average 35 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #550,172 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Indivior has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "With science, compassion, and purpose, we are Powering Recovery, Renewing Hope." (Meta description: 11 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: Microdata (Schema.org), og:title, og:description, og:image, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram; no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Indivior scores 56/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Indivior has a limited AI-visibility profile at 56/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (68/100) and its weakest is trust (33/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #550,172 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Indivior from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Indivior?", Claude could identify the brand as of August 2026. Indivior is a pharmaceutical company that specializes in treatments for opioid use disorder and other addiction-related conditions, best known for Suboxone (buprenorphine/naloxone) and long-acting injectable treatments like Sublocade. Best known for Suboxone, a leading medication for opioid addiction treatment.
When asked "Best brands similar to Indivior?", Claude would recommend Indivior as of August 2026. It's a major player in addiction treatment pharmaceuticals, so it would come up naturally in discussions of opioid use disorder medications or similar specialty pharma companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Indivior's main competitors include Alkermes, Braeburn Pharmaceuticals, Camurus, Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals (81/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Indivior and Mallinckrodt Pharmaceuticals are competitors in Healthcare. Brand Analyzer scores Indivior at 82/100 and Mallinckrodt Pharmaceuticals at 81/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Indivior include Alkermes, Braeburn Pharmaceuticals, Camurus, Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals (81/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Indivior is a specialty pharmaceutical company headquartered in Richmond, Virginia, founded in 1994. It is owned by Northern Cross and is singularly focused on developing treatments for opioid use disorder.
Sources: Indivior official site
Indivior has moderate AI-search visibility, scoring 56/100 on Brand Analyzer's AI visibility composite (visibility 68, trust 33, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Indivior official site
Indivior was founded in 1994. Indivior operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Indivior is headquartered in Richmond. Indivior operates in the Healthcare category.
Sources: Wikidata
Indivior develops and provides evidence-based pharmaceutical treatments for opioid use disorder, combining scientific research with a mission to expand access to care, reduce stigma, and support long-term recovery for affected individuals.
Sources: Indivior official site
Indivior scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Indivior official site
Indivior can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Indivior official site
Indivior's offerings are used by individuals affected by opioid use disorder, as well as healthcare providers and members of the broader medical and pharmaceutical community involved in addiction treatment.
Sources: Indivior official site
Indivior is known for its specialized focus on opioid use disorder treatment, positioning itself as a pioneer in addiction medicine with over 25 years of scientific innovation in this area.
Sources: Indivior official site
Indivior is owned by or part of Northern Cross. Indivior operates in the Healthcare category.
Sources: Wikidata
Ranked closest to Indivior: Houston Methodist (82/100), Himalayan Institute (82/100), Marini SkinSolutions (82/100), Jazz Pharmaceuticals (82/100).
A step up - brands to learn from: Oura (91/100), Olay (91/100).
Category leader: Elsevier (96/100).